Advanced Immune Monitoring with PepMix™ Peptide Pools!

Precise immune monitoring to evaluate responses and changes of the immune system during and after therapy is critical in pre-clinical and clinical research and development. The selection of an appropriate and reliable antigen source has a crucial impact on the success of such studies. 

Peptides are Better Antigens! 

• Peptides and pools mimic protein antigens or epitopes 
• Peptides can be synthesized with high purity, low bioburden and sterile 
• High batch-to-batch reproducibility 
• Precise quality control during production 
• No antigen expression required, avoiding bacterial contamination 
• ADCF policy 

Work with JPT – The Peptide Expert - and take advantage of our unparalleled peptide quality & customer service. Our PepMix™ Peptide Pools have been used and validated in many immune monitoring studies. We have more than 500 PepMix™ Peptide Pools in stock: 

• PepMix™ for TAAs
  
• PepMix™ for Infectious Disease Antigens
• PepMix™ for other antigens
• Custom PepMix™   
  

Case Studies using PepMix™ 

1. Vaccine Development: In recent years, PepMix™ has been pivotal in several high-profile vaccine development projects. Several of the COVID vaccines have been developed with SARS-CoV2 PepMixes ™ and our control pool CEFX as stimulating agent during immune monitoring. With PepMix™ you are able to measure immune responses effectively, providing critical data about vaccine efficacy. 

Selected Publications: 

• Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled Trial
  Malahe et al., Transplantation (2024) - PMID: 38902860 
• A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2 Koseki et al., Vaccines (2023) - PMID: 38140172 
• Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial
  Øverbø et al., Vaccine (2023) - PMID: 36599736 
• Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
  Pannus et al., Plos Global Public Health (2022) - PMID: 36962838 
• BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
  Sahin et al., Nature (2021) – PMID: 34044428 
• A SARS-CoV-2 mRNA Vaccine — Preliminary Report
  Jackson et al., N Engl J Med. (2020) – PMID: 32663912 

• BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2
  Vogel et al., Nature (2021) – PMID: 33524990 
• Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman Primates
  Corbett et al., N Engl J Med. (2020) – PMID: 32722908 

• Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
  Mercado et al., Nature (2020) – PMID: 32731257 
• A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
  Sanchez-Felipe et al., Nature (2021) – PMID: 33260195 
• SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice
  Tian et al., Nature Communications (2021) – PMID: 33446655 
• Application Note: “Cross-reactive T cells enhance immune responses in SARS-CoV-2 infection and vaccination” by Lucie Loyal & Andreas Thiel (Charité Berlin) 

2. Disease Diagnostics: PepMix™ has also played a crucial role in disease diagnostics. Our peptide pools are often used to monitor the immune response of patients undergoing treatment. This application highlights not only the diagnostic potential of PepMix™ but also its capability to track the progression and treatment response of infectious diseases accurately. To get specific and accurate information of a disease, the use of synthetic peptides in diagnostics have increased in the last few decades, because of their high purity profile and ability to get modified chemically. 

Selected Publications: 

• CD3-downregulation identifies T-helper-cells with superior functionality and distinct metabolism in SARS-CoV2-vaccination- and recall-antigen-specific immunity
  Sattler et al., JCI Insight (2024) – PMID: 38206757 
• Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans
  Harrer et al., Journal of Infectious Diseases (2024) – PMID:  38195212 
• Enhanced detection of antigen-specific T cells by a multiplexed AIM assay
  Lemieux et al., Cell Rep Methods (2024) – PMID: 38228152 
• T Cell Responses against Orthopoxviruses in HIV-Positive Patients
  Stefanie et al., Vaccines (2024) – PMID: 38400115 
• Functional Immune Monitoring of BK Virus And Donor‐Specific T‐cell Effector Immune Responses to Guide Treatment Decision‐Making After Kidney Transplantation; an Illustrative Case Report And Literature Review
  Lepore et.al., Transplant Infectious Disease (2020) – PMID: 33070461 
• Cytomegalovirus (CMV) Immune Monitoring with ELISPOT and QuantiFERON-CMV Assay in Seropositive Kidney Transplant Recipients
  Lee et al., Plos One (2017) – PMID: 29232714 
• Immune Monitoring to Predict and Prevent Infection
  Palmer et al., US Patent 20,160,377,602, 2016 
• Application Note: “Developing Multi-HIV Antigen Specific T cells as a Component of a Cure Strategy” by S. Lam, C. R. Cruz and C. Bollard (Center for Cancer and Immunology Research, Washington DC) 

3. Immune Toxicity of Biologics: An understanding of the immune toxicity of biologics or unwanted immunogenicity is essential for safe therapeutic development, especially when using viral vectors or CRISPR/Cas9. PepMix™ is utilized to assess unwanted immune responses in patients treated with gene therapy. The studies underscored the importance of immune monitoring in predicting and managing potential adverse effects, ensuring patient safety and treatment efficacy. 

Selected Publications: 

• LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
  Musher et al., The Lancet Oncology (2024) – PMID: 38547893 
• Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial
  Wang et al., Signal Transductions and Targeted Therapy (2024) – PMID: 38653979 
• Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques
  Zabaleta et al., Molecular Therapy (2022) – PMID: 35546782 
• Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
  Casazza et al., Nature Medicine (2022) – PMID: 35411076 
• Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors
  Stone et al., Human Gene Therapy (2021) – PMID: 32998579 

Go to our website for more PepMix™ references!   

ISO Plus Quality Grade for GLP Compliance 

We are proud to offer our ISO Plus quality grade, designed to meet Good Laboratory Practice (GLP) compliance. This includes the use of dedicated equipment and consumables, as well as updated Certificates of Analysis (CoA) and Material Safety Data Sheets (MSDS) with cytotoxicity information. These enhancements ensure that our products not only meet but exceed the stringent requirements of GLP, providing you with reliable and reproducible results for your critical studies.   

Learn More 

For detailed illustrations, references, and protocols on how PepMix™ can enhance your research, please visit our website. Our comprehensive resources provide in-depth information on the application and benefits of our peptide pools, ensuring you have all the tools you need to succeed in your immune monitoring endeavors. 

Contact Us 

Our team of experts is always here to support your research needs. Contact us today to learn how PepMix™ can advance your immune monitoring projects.